Ignite Creation Date:
2024-05-06 @ 12:30 PM
Last Modification Date:
2024-10-26 @ 12:59 PM
Study NCT ID:
NCT03773302
Status:
TERMINATED
Last Update Posted:
2024-05-08
First Post:
2018-12-10
Brief Title:
Phase 3 Study of BGJ398 Oral Infigratinib in First Line Cholangiocarcinoma With FGFR2 Gene FusionsTranslocations
Sponsor:
QED Therapeutics Inc
Organization:
QED Therapeutics Inc
Key Dates - Follows AllAPIJSON File Order
Start Date:
2019-12-27
Start Date Type:
ACTUAL
Primary Completion Date:
2023-03-02
Primary Completion Date Type:
ACTUAL
Completion Date:
2023-03-02
Completion Date Type:
ACTUAL
First Submit Date:
2018-12-10
First Submit QC Date:
December 10 2018
Study First Post Date:
2018-12-12
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
2024-05-08
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-04-15
Last Update Post Date:
2024-05-08
Last Update Post Date Type:
ACTUAL